Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS

Key Points

• Assenagon Asset Management increased its Evolus stake by 51.8% in the second quarter, adding 310,035 shares to own 908,180 shares worth approximately $6.3 million. Institutional investors collectively own 90.69% of Evolus.
• Analyst sentiment is generally positive: four analysts rate Evolus a Buy, one rates it Hold and one rates it Sell. The stock has a consensus rating of “Moderate Buy” and an average price target of $14.50.
• Evolus shares opened at $8.34, near their 52-week high of $8.43, and remain above both the 50-day moving average of $6.57 and the 200-day average of $5.58.

Assenagon Asset Management S.A. lifted its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 51.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 908,180 shares of the company's stock after acquiring an additional 310,035 shares during the period. Assenagon Asset Management S.A. owned approximately 1.38% of Evolus worth $6,303,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Larson Financial Group LLC boosted its position in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock worth $33,000 after purchasing an additional 2,837 shares during the period. Meeder Asset Management Inc. purchased a new position in Evolus in the fourth quarter valued at about $34,000. Wexford Capital LP acquired a new position in shares of Evolus during the third quarter worth about $37,000. Aquatic Capital Management LLC acquired a new position in shares of Evolus during the third quarter worth about $48,000. Finally, State of Wyoming purchased a new stake in shares of Evolus in the fourth quarter worth about $63,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Evolus from a "hold" rating to a "buy" rating in a research note on Saturday. Weiss Ratings upgraded Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 15th. Finally, BTIG Research restated a "buy" rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $14.50.

Evolus Price Performance

Shares of Evolus stock opened at $8.34 on Wednesday. The business has a 50-day moving average of $6.57 and a 200-day moving average of $5.58. The company has a market capitalization of $550.86 million, a PE ratio of -16.04 and a beta of 1.35. Evolus, Inc. has a 1-year low of $3.86 and a 1-year high of $8.43.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source